Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Mar 10, 2021 9:23am
125 Views
Post# 32761377

RE:RE:Big Pharma

RE:RE:Big Pharma
Harper75 wrote: We all have been thinking Big Pharma could/would/should be all over this platform for years now.  What's with the "around the corner" comments this morning?  


We know Big Pharma started to gain an interest as of August 2020 and we know we had one Big Pharma in the data room around that period.

We also know Dan had no interest in entertaining Big Pharma at that time ... not yet ... as he had many other things that needed to happen, complete data collection from P2B, external business studies, IND enabling studies, academic studies and new drug development - all incorporated into the strategic plan to generate value.

We are still in the early days of generating value and we're going to file the IND with FDA anytime now.  Cash is in the bank and Big Pharma discussions are still in their infancy.

I would hold out for bigger money too - as we generate mare value.  We're in no rush - cash in the bank and a killer product.  If management believes in the product, they're better off dancing with potential partners to find the right one.  With each passing day, the value goes up.

IMO
<< Previous
Bullboard Posts
Next >>